lotrevaA familiar name is not a complete identity.
TB-500 is a name encountered in research-material discussions, but the name alone is not enough to match a supplied sample to a publication. The exact amino-acid sequence and chemical modifications belong in the evidence record. Two materials can have related names while representing different molecular entities.
What the analytical literature identified.
Esposito and colleagues reported identifying an N-terminally acetylated seven-residue fragment, Ac-LKKTETQ, in a TB-500 formulation. Their work used chromatographic and mass-spectrometric analysis. This establishes what was identified in the investigated formulation; it does not verify every product currently marketed with that name.
Sources: Esposito et al. (2012): chemical identification of a TB-500 formulation
Full-length thymosin beta-4 is different.
The foundational chemical characterization of thymosin beta-4 described a 43-residue peptide. A seven-residue fragment and a 43-residue peptide should therefore have separate source records. Acetylation is also an identity detail, not something to omit when comparing a label, a method and a paper.
| Record | Identity detail | Evidence boundary |
|---|---|---|
| TB-500 formulation in the 2012 identification paper | Ac-LKKTETQ; acetylated fragment | Analytical characterization of the investigated material |
| Full-length thymosin beta-4 in the foundational paper | 43-residue peptide | Chemical characterization of the full peptide |
| An independently supplied sample | Requires its own identity and lot documentation | Cannot be inferred from either publication |
Sources: Low and Goldstein (1982): chemical characterization of thymosin beta-4
Detection is not an efficacy trial.
A separate 2012 analytical paper described detecting TB-500-related analytes in equine plasma and urine. Developing a method to detect a substance is different from testing whether it improves a health outcome. Read the study objective before treating the presence of an animal experiment as evidence of benefit.
Sources: Ho et al. (2012): analytical detection of TB-500 in equine samples
The safety entry also identifies a fragment.
FDA’s entry names the thymosin beta-4 fragment LKKTETQ, also called TB-500, and describes potential immunogenicity concerns and missing human-exposure information. Keep that exact identity visible rather than merging the entry with evidence about a different full-length material.
Sources: FDA: bulk substances with potential significant safety risks
A better way to organize the evidence.
Create separate fields for the marketed name, exact sequence, terminal modifications, analytical sample identifier and supplier lot. If a source does not disclose one of those fields, mark it as not documented. Do not fill the gap by borrowing a sequence from another vendor’s page.
Only attach a paper to a material after checking the identity match. Even a match does not establish clinical equivalence or replicate the paper’s findings in the supplied lot. This article provides no human-use instructions or claims of verified Lotreva testing.